Mar. 17 at 1:20 PM
JPMorgan⬆️
$EWTX's PT to
$45 from
$34, plus added to the 'Analyst Focus List,' while reiterating at an Overweight rating, and said that remains +VE on shares in anticipation of a # of catalyst across the Co's pipeline.
$CYTK $BMY
$CAPR
Here's what JPMorgan had to say:::For 2026, we continue to remain positive on EWTX in anticipation of a number of catalysts across the pipeline, particularly renewed interest in EDG-7500, a novel, or al cardiac sarcomere modulator and the broader cardiovascular/hypertrophic cardiomyopathy (HCM) space.
Recall, EDG-7500 does not bind to the myosin motor head and instead indirectly regulates myosin by targeting complex sarcomere protein-protein interactions that control contraction and relaxation processes.
JPMorgan also said—the full 12 week data in Q2 will be meaningful for the fundamental view on EDG-7500—it increasingly likes the setup for Edgewise in 2026.
